Actively Recruiting
A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation
Led by Icahn School of Medicine at Mount Sinai · Updated on 2025-09-25
22
Participants Needed
1
Research Sites
44 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a study assessing the feasibility of performing an anti-aging intervention which is a combination of an exercise regimen, spermidine supplementation, and either rapamycin or lamivudine.
CONDITIONS
Official Title
A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 65-80 years old
- Current or former smokers
- Body Mass Index (BMI) between 25 and 32
- No cancer requiring active therapy within the last 2 years
- No autoimmune disease requiring disease modifying agents
- No chronic kidney disease stage 3/4 or end stage renal disease
- No class 3 or 4 heart failure
You will not qualify if you...
- Cancer requiring active therapy within the last 2 years
- Autoimmune disease requiring disease modifying agents
- Receiving immune modifying biologic therapies
- Chronic kidney disease stage 3/4 or end stage renal disease
- History of metabolic dysfunction-associated steatohepatitis
- Known chronic viral infections such as HIV or active Hepatitis B or C, or history of genital HSV (except cleared hepatitis B or C with documented negative PCR)
- Class 3 or 4 heart failure, or myocardial infarction or cerebrovascular event in past 6 months
- Uncontrolled diabetes mellitus
- History of clinically significant interstitial lung disease
- Active wound healing from recent injury or surgery
- Signs or symptoms of clinically significant acute infectious illness
- Evidence of active or latent tuberculosis
- Nephrotic range proteinuria
- Received a live virus vaccine within one month of study start
- Uncontrolled hypertension (systolic >160; diastolic >100)
- Inherited primary immunodeficiency
- History or current clinically significant chronic liver disease
- Receiving chronic immunosuppressive therapy
- Use of medications that interact with rapamycin (if assigned to rapamycin group) such as strong CYP3A4/P-gp inhibitors or inducers, or ACE inhibitors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mount Sinai Hospital
New York, New York, United States, 10029
Actively Recruiting
Research Team
T
Thomas Marron, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here